literature

HIV mutation literature information.

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.

PMID: 11170982 2001 The Journal of infectious diseases

Abstract: Previous zidovudine or lamivudine use and presence at baseline of the M184V reverse-transcriptase mutation did not impact virologic response.

Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.

PMID: 11181387 2001 Antimicrobial agents and chemotherapy

Abstract: Recently, it has been shown that a new mutational pattern (the E44D/A and/or V118I mutation) confers moderate phenotypic lamivudine resistance in the absence of the M184V mutation.

Abstract: These mutations are more stable than the M184V substitution during antiretroviral treatment interruptions.

Abstract: They are always associated with zidovudine resistance-associated mutations, even in the absence of M184V.

Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.

PMID: 11242181 2001 Journal of acquired immune deficiency syndromes (1999)

Abstract: A median infectious dose (IC50) increase of fourfold for any drug was found in 7 patients, and in 2 was > tenfold for zidovudine (genotype M41L + T215Y) and lamivudine (genotype M184V), respectively.

International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.

PMID: 11264998 2001 Journal of acquired immune deficiency syndromes (1999)

Abstract: Other features of NRTI resistance, such as the theoretic reversal of zidovudine resistance associated with the M184V mutation or the powerful influence of the Q151M multiple-drug resistance mutation, have revealed the unpredictable nature of HIV resistance and how much we still need to learn.

Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.

PMID: 11311097 2001 JAMA

Abstract: The M184V lamivudine resistance mutation was detected at 6 weeks after delivery in specimens from 52 of 132 women.

HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort.

PMID: 11316997 2001 AIDS (London, England)

Abstract: However, the data suggest that some individuals (harboring a M184V mutation in RT or a V82I in protease) may have benefited from pre-therapy resistance tests.

HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.

PMID: 11371689 2001 AIDS (London, England)

Abstract: CONCLUSIONS: Substantial decreases in plasma and CSF HIV-1 RNA following addition of ABC were not precluded by baseline HIV-1 NRTI-associated mutations, including the M184V mutation, but non-responders commonly harbored multiple ZDV/d4T-associated mutations.

Abstract: RESULTS: Sixty out of sixty-seven subjects with baseline plasma HIV-RT sequence data harbored virus with > or = 1 NRTI-associated mutations; 50 out of 67 had the M184V mutation.

Resistance to antiretroviral therapy among patients in Uganda.

PMID: 11391172 2001 Journal of acquired immune deficiency syndromes (1999)

Abstract: Among 8 patients taking lamivudine, phenotypic resistance was found for 9 (90%) of 10 specimens and was associated with an M184V mutation in all nine cases.

Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

PMID: 11417760 2001 Antiviral therapy

Abstract: At the time of the regimen shift, all the subjects exhibited a high-level phenotypic resistance to both zidovudine and lamivudine with changes at codons 70-219 in 100% of cases, at codon 215 in 13 of 16 patients, and the M184V substitution in 13/16 patients.

Abstract: These findings suggest the possibility of achieving a viral load response to didanosine-containing regimens in patients with reverse transcriptase (RT) M184V mutations who were previously treated with this drug and its possible use in salvage combinations.

Reverse transcriptase incorporation of 1,5-anhydrohexitol nucleotides.

PMID: 11470872 2001 Nucleic acids research

Abstract: Investigation of incorporation of the altritol anhydrohexitol nucleotide of adenine in the presence of M184V and Vent (exo(-)) DNA polymerase proved that an adjacent hydroxyl group on C3 of 1,5-anhydrohexitol-ATP has a detrimental effect on the substrate activity of the six-ring analogue.

Abstract: Subsequently, several HIV-1 mutants (4xAZT, 4xAZT/L100I, L74V, M184V and K65A) were likewise analysed, resulting in selection of K65A and, in particular, M184V as the most succesful mutant HIV-1 reverse transcriptases capable of elongating a DNA primer with several 1,5-anhydrohexitol adenines in an efficient way.

Browser Board

Co-occurred Entities

Filtrator